The goal of this clinical trial is to learn if bronchoscopic lung volume reduction with endobronchial thermal liquid ablation (ETLA) works to treat severe emphysema in terms of feasibility and safety.
Participants will:
* Have up to two ETLA procedures * Complete five clinic follow-up visits and two virtual follow-up visits.
Age ≥ 40 years old
Diagnosis of COPD with FEV1/FVC less than 0.7 post-bronchodilation
Post-bronchodilator Forced Expiratory Volume (FEV1) ≥ 20% and ≤ 49% of predicted value
Total lung capacity (TLC) ≥ 100% predicted
Body mass index (BMI) < 16 kg/m² or ≥ 33 kg/m²
DLCO < 20% predicted
Chronic bronchitis as defined by cough and sputum production for at least 3 months per year for two consecutive years, in the absence of other conditions that can explain these symptoms
75ml or greater sputum production per day most days of the week
Morair Medtech, LLC
Lead sponsor